Clinical Trials Search
Clinical Trial 19089
Cancer Type: Malignant Hematology
Interventions:Thymoglobulin; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Study Type: Treatment
Phase of Study: Phase II
Investigators:
- Lia Perez
Study Title
Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (CHAMP)
Summary
The purpose of this study is to learn how well severe aplastic anemia (SAA) participants do with transplants that use unrelated cord blood and transplants that use haploidentical bone marrow. Moffitt Cancer Center will only enroll participants with a haploidentical bone marrow donor.
Objective
Assess overall survival (OS) separately in 2 cohorts (unrelated cord blood [UCB] and haploidentical [haplo] marrow) at 1 year post-hematopoietic stem cell transplantation (HSCT) in patients with severe aplastic anemia (SAA). Assess overall survival (OS) separately in 2 cohorts (unrelated cord blood [UCB] and haploidentical [haplo] marrow) at 1 year post-hematopoietic stem cell transplantation (HSCT) in patients with severe aplastic anemia (SAA).